Hansoh Pharmaceutical Group Co (FRA:3KY) Other Stockholders Equity: €113 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3KY Hansoh Pharmaceutical Group Co Ltd FRA:3KY
90 GF Score
Price €3.64
GF Value €3.05
Valuation Modestly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Other Stockholders Equity?

Hansoh Pharmaceutical Group Co FRA:3KY +0.97% 90 Other Stockholders Equity is €113 Mil as of Dec. 2025. GuruFocus rates FRA:3KY with a GF Score™ of 90/100 and a GF Value™ of €3.05 (Modestly Overvalued).

Hansoh Pharmaceutical Group Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €113 Mil.

Hansoh Pharmaceutical Group Co's quarterly Other Stockholders Equity declined from Dec. 2024 (€221 Mil) to Jun. 2025 (€165 Mil) and declined from Jun. 2025 (€165 Mil) to Dec. 2025 (€113 Mil).

Hansoh Pharmaceutical Group Co's annual Other Stockholders Equity increased from Dec. 2023 (€167 Mil) to Dec. 2024 (€221 Mil) but then declined from Dec. 2024 (€221 Mil) to Dec. 2025 (€113 Mil).

Hansoh Pharmaceutical Group Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Other Stockholders Equity Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,791.01 115.54 167.14 220.60 113.17

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.14 187.20 220.60 164.97 113.17
FRA:3KY
90GF Score
Hansoh Pharmaceutical Group Co Ltd FRA:3KY
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €113 Mil mean?
Hansoh Pharmaceutical Group Co (FRA:3KY) has a Other Stockholders Equity of €113 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hansoh Pharmaceutical Group Co and its competitors.
Is Hansoh Pharmaceutical Group Co's Other Stockholders Equity too high?
Hansoh Pharmaceutical Group Co's current Other Stockholders Equity is €113 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Other Stockholders Equity compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Other Stockholders Equity of €113 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Other Stockholders Equity is €113 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (FRA:3KY) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.05, compared to a current price of €3.64 — trading 19.4% above its estimated fair value. The current Other Stockholders Equity is €113 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (FRA:3KY), the current Other Stockholders Equity is €113 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (FRA:3KY) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of €3.64 is trading 19.4% above its estimated GF Value™ of €3.05. GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for FRA:3KY:

  • Other Stockholders Equity: €113 Mil
  • GF Value™: €3.05 vs. price of €3.64 (19.4% above fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the FRA:3KY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score

Get the complete analysis for FRA:3KY

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.64
Price
€3.05
GF Value